Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Down 3.0 %

NASDAQ CYCC opened at $0.96 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $11.34. The stock has a 50 day moving average of $1.26 and a 200-day moving average of $1.71. The company has a market cap of $1.40 million, a PE ratio of -0.04 and a beta of 0.52.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same quarter in the previous year, the company earned ($6.60) earnings per share. As a group, sell-side analysts predict that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Institutional Trading of Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the SEC. 23.58% of the stock is owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.